ATYR — aTyr Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $319.89m
- $249.01m
- $0.24m
- 15
- 4
- 100
- 33
Annual cashflow statement for aTyr Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16.2 | -33.8 | -45.3 | -50.4 | -64 |
| Depreciation | |||||
| Non-Cash Items | 2.62 | 2.81 | 4.06 | 1.57 | 1.11 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.26 | -2.59 | -0.833 | 15 | -6.92 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -15.3 | -33.1 | -41.9 | -33.2 | -69.1 |
| Capital Expenditures | -0.202 | -0.192 | -1.64 | -4.21 | -0.065 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 7.1 | -91.4 | 48.9 | -15.9 | 17.3 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 6.9 | -91.6 | 47.2 | -20.1 | 17.2 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.1 | 110 | 5.45 | 66.2 | 39.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.74 | -14.6 | 10.8 | 12.9 | -12 |